Nexalin Technology, Inc. (NXL)

0.7305 -0.0244 (-3.23%) As of 09:44AM EDT. Market open.

Nexalin Technology, Inc.

1776 Yorktown
Suite 550
Houston, TX 77056
United States
(832) 260-0222
https://www.nexalin.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark White	President, CEO, CFO & Director	442.5k	N/A	1962
Dr. David Owens M.D.	Chief Medical Officer & Director	42.8k	N/A	1962
Mr. Michael Nketiah	Senior Vice-President of Quality, Regulatory & Clinical Affairs	280k	N/A	1976
Ms. Marilyn Elson	Controller	382.72k	N/A	1953
Mr. John Patrick Claude	Co-Founder and Director of Engineering & Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Corporate governance

Nexalin Technology, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.